STAT

MARCH 3, 2024

WASHINGTON — Doctors will get a 1.68% pay hike in Medicare starting March 9 under a deal struck over the weekend to fund part of the government. The pay bump is among multiple Medicare payment policies that now will run until the end of December. That year-end deadline lines up with the expiration of telehealth pay policies , setting the stage for a large health legislative package and giving Congress another shot at aligning hospital and doctor office payments and reforming the business

Packaging 126

Packaging Hospitals 126

The FDA Law Blog

MARCH 3, 2024

By Steven J. Gonzalez & JP Ellison — The most recent version of the BIOSECURE Act (the “Act”) was introduced in the U.S. House of Representatives ( H.B. 7085 ) and Senate ( S.B. 3558 ) on January 25, 2024. This proposed legislation should be of interest to any biotechnology companies that want to do business with the federal government in the future.

Packaging 102

Packaging FDA 102

pharmaphorum

MARCH 3, 2024

Avidity Biosciences files $400m private placement as it prepares for phase 3 trial of lead antibody oligonucleotide conjugate AOC 1001 in rare disease DM1

105

105

OctariusRx

MARCH 3, 2024

March is malignant hyperthermia awareness and training month and at OctariusRx, we are always focused on patient safety. Join us this month as we raise awareness and support the cause. Malignant hyperthermia (MH) is a rare, inherited disorder that can affect patients who are receiving anesthesia for surgery or other procedures. Being prepared is paramount for patient safety.

83

83

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MARCH 3, 2024

Federal judge rules against AstraZeneca in lawsuit challenging Medicare drug pricing negotiation under the Inflation Reduction Act

106

106

The FDA Law Blog

MARCH 3, 2024

By Jeffrey N. Gibbs & Allyson B. Mullen — FDA’s proposed rule to regulate laboratory developed tests (LDTs) as devices took one more step towards being finalized – and to a likely judicial showdown. On March 1, the Office of Management and Budget (OMB) received the draft final LDT rule for review ( here ). The LDT rule has moved forward with astonishing speed, advancing from the release of the proposed rule on October 3, 2023 to OMB in less than five months.

FDA 64

FDA 64

Pharma Mirror

MARCH 3, 2024

Presented by BetterHelp. Some people still aren’t aware that men and non-gestational parents can also experience emotional dysregulation after the birth of a child. Luckily, the conversation surrounding women and gestational parents and postpartum depression has gained a lot of awareness. However, are we forgetting the other half of the parenting dyad?

52

52

Med Ed 101

MARCH 3, 2024

Blood pressure medications are commonly used in practice. You should know some of the major interactions with these medications. In this blog post, I will lay out my top 5 antihypertensive drug interactions and also share some information on how these interactions can affect our patients. Hyperkalemia Risk ACEIs and ARBs are atop the list […] The post Top 5 Antihypertensive Drug Interactions appeared first on Med Ed 101.

52

52

BioPharm

MARCH 3, 2024

CPHI North America is a three-day event offering opportunities to learn, innovate, and network in the pharmaceutical industry.

40

40

BioPharm

MARCH 3, 2024

The 6th Treg-Directed Therapies Summit will feature leading industry and academic experts in the Treg therapy field.

40

40

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA